Patents by Inventor Pingda Ren

Pingda Ren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250255869
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewing's sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: January 16, 2025
    Publication date: August 14, 2025
    Inventors: Francis BURROWS, Linda V. KESSLER, Liansheng LI, Pingda REN, Yi WANG, Tao WU, Jingchuan ZHANG
  • Publication number: 20250197400
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Application
    Filed: July 3, 2024
    Publication date: June 19, 2025
    Inventors: Pingda REN, Michael MARTIN, Paul ISBESTER, Benjamin S. LANE, Jason KROPP
  • Publication number: 20250170122
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: January 21, 2025
    Publication date: May 29, 2025
    Inventors: Pingda REN, Yi LIU, Troy Edward WILSON, Liansheng LI, Katrina CHAN, Christian ROMMEL
  • Publication number: 20250154133
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, L3, E, m1, m2 and * are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: July 5, 2024
    Publication date: May 15, 2025
    Inventors: Liansheng Li, Jun Feng, Tao Wu, Yuan Liu, Yi Wang, Pingda Ren, Yi Liu
  • Publication number: 20250136609
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, L1, L2, L3, A1, A2, A3, A4, G1, G2, E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: September 11, 2024
    Publication date: May 1, 2025
    Inventors: Liansheng LI, Jun FENG, Tao WU, Yuan LIU, Yi WANG, Alana K. BORUM, Pingda REN, Yi LIU
  • Patent number: 12286427
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: July 19, 2024
    Date of Patent: April 29, 2025
    Assignee: Kumquat Biosciences Inc.
    Inventors: Yi Liu, Pingda Ren, Liansheng Li, Zhimin Zhu, Xiuwen Zhu
  • Patent number: 12234244
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, have the following structure: wherein A, L1, L2, Q, R1, R2a, R3a, R3b, R4a, R4b, R9, R10, Y, and Z are as exemplified herein. Pharmaceutical compositions comprising such compounds, methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, and methods associated with preparation of such compounds are also provided.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: February 25, 2025
    Assignee: Araxes Pharma LLC
    Inventors: Liansheng Li, Jun Feng, Tao Wu, Pingda Ren, Yi Liu, Yuan Liu, Yun Oliver Long
  • Patent number: 12209102
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: May 17, 2024
    Date of Patent: January 28, 2025
    Assignee: Kumquat Biosciences Inc.
    Inventors: Pingda Ren, Liansheng Li, Baogen Wu, Xiaoming Li, Zhiyong Chen, Siling Zhao, Yi Liu, Xiuwen Zhu
  • Patent number: 12195465
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Grant
    Filed: October 30, 2023
    Date of Patent: January 14, 2025
    Assignee: Kumquat Biosciences Inc.
    Inventors: Baogen Wu, Pingda Ren, Zhiyong Chen, Yi Liu
  • Publication number: 20240425522
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: May 17, 2024
    Publication date: December 26, 2024
    Inventors: Pingda Ren, Liansheng Li, Baogen Wu, Xiaoming Li, Zhiyong Chen, Siling Zhao, Yi Liu, Xiuwen Zhu
  • Publication number: 20240425525
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: July 29, 2024
    Publication date: December 26, 2024
    Inventors: Pingda Ren, Liansheng Li, Baogen Wu, Xiaoming Li, Zhiyong Chen, Siling Zhao, Yi Liu, Xiuwen Zhu
  • Publication number: 20240398828
    Abstract: The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and research tools. The subject compositions and methods are particularly useful for potentiating immune response and/or applicable for treating cancer and other diseases.
    Type: Application
    Filed: May 20, 2024
    Publication date: December 5, 2024
    Inventors: Liansheng Li, Xiuwen Zhu, Pingda Ren, Jonathan Deane, Lomon So, Yi Liu
  • Publication number: 20240390389
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of certain oncogenic proteins.
    Type: Application
    Filed: April 12, 2024
    Publication date: November 28, 2024
    Inventors: Baogen Wu, Liansheng Li, Pingda Ren, Yi Liu, Siling Zhao, Xiaoming Li, Zhiyong Chen, Zhimin Zhu
  • Publication number: 20240383888
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: July 19, 2024
    Publication date: November 21, 2024
    Inventors: Yi Liu, Pingda Ren, Liansheng Li, Zhimin Zhu, Xiuwen Zhu
  • Publication number: 20240368191
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.
    Type: Application
    Filed: November 10, 2023
    Publication date: November 7, 2024
    Inventors: Xiaoming Li, Liansheng Li, Baogen Wu, Yuan Liu, Rasmus Hansen, Zhiyong Chen, Pingda Ren
  • Patent number: 12134620
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, L1, L2, L3, A1, A2, A3, A4, G1, G2, E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: November 5, 2024
    Assignee: ARAXES PHARMA LLC
    Inventors: Liansheng Li, Jun Feng, Tao Wu, Yuan Liu, Yi Wang, Alana K. Borum, Pingda Ren, Yi Liu
  • Publication number: 20240358703
    Abstract: The present disclosure provides methods for treating hematological malignancies and Ewing's sarcoma using menin inhibitors. Compositions for use in these methods are also provided.
    Type: Application
    Filed: January 19, 2024
    Publication date: October 31, 2024
    Inventors: Francis BURROWS, Linda V. KESSLER, Liansheng LI, Pingda REN, Yi WANG, Tao WU, Jingchuan ZHANG
  • Publication number: 20240352028
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: January 18, 2024
    Publication date: October 24, 2024
    Inventors: Liansheng LI, Jun FENG, Tao WU, Pingda REN, Yi LIU, Yuan Liu, Yun Oliver Long
  • Patent number: RE50490
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, B, G1, G2, L1, L2, m1, m2, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: July 15, 2025
    Assignee: Araxes Pharma LLC
    Inventors: Liansheng Li, Jun Feng, Yun Oliver Long, Yuan Liu, Tao Wu, Pingda Ren, Yi Liu
  • Patent number: RE50527
    Abstract: Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: August 12, 2025
    Assignee: Araxes Pharma LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng, Tao Wu